Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: Results at week 24

Annals of the Rheumatic Diseases

Volumn 73, Issue 5, 2014, Pages 831-837

  Saadoun, David ^a,b   Rigon, M Resche ^c   Thibault, V ^d   Longuet, M ^a   Pol, S ^e   Blanc, F ^f   Pialoux, G ^g   Karras, A ^h   Bazin Karra, D ⁱ   Cazorla, C ^j   Vittecoq, D ^k   Musset, L ^d   Decaux, O ^l   Ziza, J M ^m   Lambotte, O ⁿ   Cacoub, Patrice ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f LAPEYRONIE HOSPITAL   (France)

^g HÔPITAL TENON   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ Ctr de Gerontologie des Hop Univ   (France)

^j Ctr Hosp Terr Nouvelle Caledonie   (France)

^k HÔPITAL PAUL BROUSSE   (France)

^l SERVICE DE RHUMATOLOGIE   (France)

^m GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

ⁿ BICÊTRE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; COMPLEMENT COMPONENT C4; CRYOGLOBULIN; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; TELAPREVIR;

ADULT; AGED; ANEMIA; ARTICLE; BREAST ABSCESS; CHOLECYSTITIS; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CRYOGLOBULINEMIA; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIVER BIOPSY; LUNG DISEASE; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OTITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PRURITUS; SKIN DISEASE; SKIN TOXICITY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TOOTH ABSCESS; URINARY TRACT INFECTION; VASCULITIS;

AGED; ANTIVIRAL AGENTS; COHORT STUDIES; CRYOGLOBULINEMIA; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VASCULITIS;

EID: 84896950918     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202770     Document Type: Article

References (24)

1. Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980;69:287-308. (Pubitemid 10036826)
2. Saadoun D, Sellam J, Ghillani-Dalbin P, et al. Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med 2006;166:2101-8. (Pubitemid 44631398)
3. Meltzer M, Franklin EC, Elias K, et al. Cryoglobulinemia - a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 1966;40:837-56.
4. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992;19;327:1490-5.
5. Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011;365:2067-77.
6. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012;64:843-53.
7. Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia:a long-term study. Blood 2010;116:343-53.
8. Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010;116:326-34.
9. Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012;64:835-42.
10. Saadoun D, Resche-Rigon M, Thibault V, et al. Antiviral therapy for hepatitis C virus - associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 2006;54:3696-706. (Pubitemid 44737183)
11. Pietrogrande M, De Vita S, Zignego AL, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011;10:444-54.
12. Mazzaro C, Franzin F, Tulissi P, et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer 1996;77:2604-13. (Pubitemid 126497594)
13. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49.
14. Musset L, Diemert MC, Taibi F, et al. Characterization of cryoglobulins by immunoblotting. Clin Chem 1992;38:798-802.
15. Brouet JC, Clauvel JP, Danon F, et al. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974;57:775-88.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
17. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994;20(1 Pt 1):15-20.
18. Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995;47: 618-23.
19. Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004;33:355-74. (Pubitemid 38887136)
20. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-24.
21. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
22. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
23. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
24. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.